165 related articles for article (PubMed ID: 33131252)
1. Novel aptamer to von Willebrand factor A1 domain (TAGX-0004) shows total inhibition of thrombus formation superior to ARC1779 and comparable to caplacizumab.
Sakai K; Someya T; Harada K; Yagi H; Matsui T; Matsumoto M
Haematologica; 2020 Nov; 105(11):2631-2638. PubMed ID: 33131252
[TBL] [Abstract][Full Text] [Related]
2. [Development of a novel aptamer blocking the interaction between the VWF A1 domain and platelet GP Ib for the treatment of arterial thrombosis].
Matsumoto M; Harada K
Rinsho Ketsueki; 2022; 63(5):393-402. PubMed ID: 35662162
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of von Willebrand factor-mediated platelet activation and thrombosis by the anti-von Willebrand factor A1-domain aptamer ARC1779.
Diener JL; Daniel Lagassé HA; Duerschmied D; Merhi Y; Tanguay JF; Hutabarat R; Gilbert J; Wagner DD; Schaub R
J Thromb Haemost; 2009 Jul; 7(7):1155-62. PubMed ID: 19422452
[TBL] [Abstract][Full Text] [Related]
4. The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo.
Mayr FB; Knöbl P; Jilma B; Siller-Matula JM; Wagner PG; Schaub RG; Gilbert JC; Jilma-Stohlawetz P
Transfusion; 2010 May; 50(5):1079-87. PubMed ID: 20070617
[TBL] [Abstract][Full Text] [Related]
5. High-resolution structure of the vWF A1 domain in complex with caplacizumab, the first nanobody-based medicine for treating acquired TTP.
Lee HT; Park UB; Jeong TJ; Gu N; Lee SH; Kim Y; Heo YS
Biochem Biophys Res Commun; 2021 Aug; 567():49-55. PubMed ID: 34144500
[TBL] [Abstract][Full Text] [Related]
6. Targeting von Willebrand factor and platelet glycoprotein Ib receptor.
Firbas C; Siller-Matula JM; Jilma B
Expert Rev Cardiovasc Ther; 2010 Dec; 8(12):1689-701. PubMed ID: 21108551
[TBL] [Abstract][Full Text] [Related]
7. Structure and function of the von Willebrand factor A1 domain: analysis with monoclonal antibodies reveals distinct binding sites involved in recognition of the platelet membrane glycoprotein Ib-IX-V complex and ristocetin-dependent activation.
De Luca M; Facey DA; Favaloro EJ; Hertzberg MS; Whisstock JC; McNally T; Andrews RK; Berndt MC
Blood; 2000 Jan; 95(1):164-72. PubMed ID: 10607699
[TBL] [Abstract][Full Text] [Related]
8. Identification of amino acid residues essential for von Willebrand factor binding to platelet glycoprotein Ib. Charged-to-alanine scanning mutagenesis of the A1 domain of human von Willebrand factor.
Matsushita T; Sadler JE
J Biol Chem; 1995 Jun; 270(22):13406-14. PubMed ID: 7539426
[TBL] [Abstract][Full Text] [Related]
9. A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease.
Jilma B; Paulinska P; Jilma-Stohlawetz P; Gilbert JC; Hutabarat R; Knöbl P
Thromb Haemost; 2010 Sep; 104(3):563-70. PubMed ID: 20589313
[TBL] [Abstract][Full Text] [Related]
10. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers.
Gilbert JC; DeFeo-Fraulini T; Hutabarat RM; Horvath CJ; Merlino PG; Marsh HN; Healy JM; Boufakhreddine S; Holohan TV; Schaub RG
Circulation; 2007 Dec; 116(23):2678-86. PubMed ID: 18025536
[TBL] [Abstract][Full Text] [Related]
11. A new mutation, S1285F, within the A1 loop of von Willebrand factor induces a conformational change in A1 loop with abnormal binding to platelet GPIb and botrocetin causing type 2M von Willebrand disease.
Stepanian A; Ribba AS; Lavergne JM; Fressinaud E; Juhan-Vague I; Mazurier C; Girma JP; Meyer D
Br J Haematol; 2003 Feb; 120(4):643-51. PubMed ID: 12588351
[TBL] [Abstract][Full Text] [Related]
12. The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease.
Jilma-Stohlawetz P; Knöbl P; Gilbert JC; Jilma B
Thromb Haemost; 2012 Aug; 108(2):284-90. PubMed ID: 22740102
[TBL] [Abstract][Full Text] [Related]
13. The aptamer ARC1779 is a potent and specific inhibitor of von Willebrand Factor mediated ex vivo platelet function in acute myocardial infarction.
Spiel AO; Mayr FB; Ladani N; Wagner PG; Schaub RG; Gilbert JC; Jilma B
Platelets; 2009 Aug; 20(5):334-40. PubMed ID: 19637097
[TBL] [Abstract][Full Text] [Related]
14. Structure-Based Cyclic Glycoprotein Ibα-Derived Peptides Interfering with von Willebrand Factor-Binding, Affecting Platelet Aggregation under Shear.
Hrdinova J; Fernández DI; Ercig B; Tullemans BME; Suylen DPL; Agten SM; Jurk K; Hackeng TM; Vanhoorelbeke K; Voorberg J; Reutelingsperger CPM; Wichapong K; Heemskerk JWM; Nicolaes GAF
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216161
[TBL] [Abstract][Full Text] [Related]
15. Purified A2 domain of von Willebrand factor binds to the active conformation of von Willebrand factor and blocks the interaction with platelet glycoprotein Ibalpha.
Martin C; Morales LD; Cruz MA
J Thromb Haemost; 2007 Jul; 5(7):1363-70. PubMed ID: 17389010
[TBL] [Abstract][Full Text] [Related]
16. Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets.
Hillery CA; Mancuso DJ; Evan Sadler J; Ponder JW; Jozwiak MA; Christopherson PA; Cox Gill J; Paul Scott J; Montgomery RR
Blood; 1998 Mar; 91(5):1572-81. PubMed ID: 9473222
[TBL] [Abstract][Full Text] [Related]
17. Targeting shear gradient activated von Willebrand factor by the novel single-chain antibody A1 reduces occlusive thrombus formation in vitro.
Hoefer T; Rana A; Niego B; Jagdale S; Albers HJ; Gardiner EE; Andrews RK; Van der Meer AD; Hagemeyer CE; Westein E
Haematologica; 2021 Nov; 106(11):2874-2884. PubMed ID: 33054112
[TBL] [Abstract][Full Text] [Related]
18. A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura.
Jilma-Stohlawetz P; Gilbert JC; Gorczyca ME; Knöbl P; Jilma B
Thromb Haemost; 2011 Sep; 106(3):539-47. PubMed ID: 21833442
[TBL] [Abstract][Full Text] [Related]
19. Platelet GpIba binding to von Willebrand Factor under fluid shear:contributions of the D′D3-domain, A1-domain flanking peptide and O-linked glycans.
Madabhushi SR; Zhang C; Kelkar A; Dayananda KM; Neelamegham S
J Am Heart Assoc; 2014 Oct; 3(5):e001420. PubMed ID: 25341886
[TBL] [Abstract][Full Text] [Related]
20. Platelet-vessel wall interactions in thrombosis and restenosis role of von Willebrand factor.
Hoylaerts MF
Verh K Acad Geneeskd Belg; 1997; 59(3):161-83. PubMed ID: 9490916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
